Real-world direct medical costs and resource utilization of immune checkpoint inhibitors in advanced NSCLC with COPD: a multicenter cost-consequence analysis from Iraq
Multicenter cost-consequence analysis shows high costs for ICI therapy in patients with advanced NSCLC and COPD, indicating resource allocation needs.
Key Points
This analysis aims to evaluate the direct medical costs and healthcare resource utilization associated with immune checkpoint inhibitors in patients with advanced NSCLC and COPD in Iraq.
Conducted a multicenter real-world cost-consequence analysis at two public oncology centers in Iraq.
Included adults with advanced NSCLC and COPD receiving first-line ICI therapy.
Assessed costs and resource use over a six-cycle horizon using a micro-costing approach.
Mean per-patient cost for atezolizumab was 13.3 million IQD (10,170 USD) and for pembrolizumab was 23.6 million IQD (18,059 USD).
Immunotherapy acquisition costs accounted for 94-97% of total costs.
Non-drug costs and response outcomes were similar between the treatment regimens.